AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$ICHR

MacKenzie Iain sold $1.0M of ICHR

MacKenzie Iain sold 20,000 shares of ICHOR HOLDINGS, LTD. (ICHR) at an average of $50.66 ($50.52–$51.59, $1.01M total) across 2 trades on 2026-09-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MacKenzie Iain
Published Sep 16, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 8:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ICHR
Neutral
medium confidence
Mentioned
$ICHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ICHRNeutralLow
01

Why it matters

Routine insider transaction with modest dollar amount; unlikely to drive significant price movement.

02

Market read

Provides a factual update on insider holdings; limited trading relevance.

03

What to watch

Potential upcoming clinical data releases could make the sale timing coincidental.

Relevance 5/10Novelty 4/10Timing: post‑market 2026‑09‑15

Background

Form 4 filing from SEC EDGAR reporting a director's stock sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$ICHRNeutralMedium confidence
Context

Director MacKenzie Iain sold 20,000 shares for $1.0M via a 10b5‑1 plan, reducing his stake to 102,427 shares.

Expected impact

Potential slight downward pressure, likely limited to short‑term volatility.

Evidence & confidence

Sale amount is under $2M and follows a pre‑arranged plan, typical for liquidity needs; no immediate catalyst.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No broader regional effect.

Global

Limited relevance; only affects ICHR shareholders.

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may simply be personal liquidity.

Key entities

  • company
    ICHR

    Ichor Holdings, Ltd., a biotech listed on NASDAQ.

  • person
    MacKenzie Iain

    Director of Ichor Holdings.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ICHR insider trading history →

Related articles

NOV 3
$ICHRMed

What Ichor (ICHR) Said on Its Q3 Earnings Call

Ichor (ICHR) reported Q3 earnings, noting supply constraints in high-end applications but improved revenue linearity. Q4 revenue is forecasted at $345M-$365M, with 8% sequential growth at the midpoint. Gross margin is expected at 16.5%±0.5%, and EPS at $0.65-$0.75. The company is investing in capacity expansion to support $3B revenue by 2027, with increased hiring and customer inventory backstopping.

finance.yahoo.com2 min
NOV 2
$ICHRHighAI 9/10

Why is Ichor Holdings stock gaining today?

Ichor Holdings (ICHR) stock rose 0.2% after reporting Q3 2026 earnings of $0.63 per share, beating estimates by $0.18. Revenue grew 37% YoY to $328.7M, slightly missing expectations. The company guided Q4 EPS to $0.65-$0.75, well above consensus. Gross margin expanded to 16.0% from 5.1% YoY, but free cash flow turned negative.

investing.com4 min
NOV 2
$ICHRMed

Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results

ICHOR HOLDINGS, LTD. (ICHR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ichor Holdings, Ltd. Announces Third Quarter 2026 Financial Results FREMONT, Calif., November 2, 2026–Ichor Holdings, Ltd. (NASDAQ: ICHR), a leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor ca

SEC EDGAR 8-K2 min